The Government Accountability Office said it will investigate potential abuses of the orphan drug program, which offers incentives to drugmakers to develop medicines for rare diseases.
The penalty would affect people buying insurance who had a lapse in coverage of more than 63 days over a year. A surcharge of 30 percent would be attached to their premiums for a year.
Spending on consumer advertising by drugmakers has increased 62 percent since 2012.
Is Republican Rep. Mark Meadows the man who would kill “Trumpcare”? He enjoys strong support in his gerrymandered western North Carolina district as he leads conservative opposition to the GOP’s plan for repealing and replacing Obamacare.
Lesser-known provisions in the Republican proposal to replace the Affordable Care Act would push some Medicaid enrollees out of coverage and cause financial pain for others.
Matching with a residency program had an added layer of stress this year for doctors-in-training from the countries affected by President Donald Trump’s travel ban.
The HHS Secretary bought stock in companies that stood to benefit from legislation he voted for and sponsored as a Georgia congressman.
A cholesterol-lowering drug called Repatha cuts the risk of heart attacks, strokes and heart-related death by 20 percent, according to a new study.
Marathon, maker of an expensive treatment for Duchenne muscular dystrophy, sells the drug for $140 million in cash and stock to PTC Therapeutics.
The numbers show that President Trump’s choice for FDA commissioner, Scott Gottlieb, has long-standing ties to pharmaceutical companies as a board member or consultant and that he had to recuse himself multiple times while working at the FDA.